Logo for Autolus Therapeutics plc

Autolus Therapeutics Investor Relations Material

Latest events

Logo for Autolus Therapeutics plc

Q3 2024

Autolus Therapeutics
Logo for Autolus Therapeutics

Q3 2024

12 Nov, 2024
Logo for Autolus Therapeutics

FDA Announcement

11 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Autolus Therapeutics plc

Access all reports
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company engaged in the development of advanced T-cell therapies for the treatment of cancer. The company leverages its proprietary technologies to engineer CAR T-cell therapies aimed at providing life-changing benefits to patients with various cancer types. Some of their key clinical-stage programs focus on therapies for conditions such as adult acute lymphoblastic leukemia and multiple myeloma. Autolus was founded in 2014, following innovative developments in cell programming technology at University College London. The company is headquartered in London, United Kingdom, and its shares are listed on the Nasdaq.